Adjuvant Sunitinib’s Role in the Treatment of RCC

(5:54)

Adjuvant Sunitinib for High Risk Renal Cell Carcinoma: Not Ready for Prime Time

(19:55)

Dr. George on the Use of Adjuvant Sunitinib in RCC

(1:35)

Adjuvant sunitinib for renal cell carcinoma

(3:49)

Selecting Patients With Renal Cell Carcinoma for Adjuvant Sunitinib Therapy

(55)

Adjuvant treatment with sorafenib or sunitinib doesn't improve outcomes in localised renal carcinoma

(4:3)

S-TRAC Phase III trial of sunitinib as adjuvant therapy in high-risk renal cell cancer patients

(2:23)

Dr. Lara on the FDA Approval of Adjuvant Sunitinib in RCC

(2:20)

Dr. Haas on Adjuvant Sorafenib or Sunitinib for RCC

(2:11)

Sunitinib for treating high-risk RCC

(1:56)

Adjuvant Sunitinib in Renal Cell Carcinoma

(3:)

Dr. Lara on the Role of Sunitinib for Renal Cell Carcinoma

(1:23)

Clinical trials in adjuvant RCC

(1:8)

The role of ICIs in the adjuvant setting for RCC

(53)

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

(9:16)

Daniel J. George, MD, on the effectiveness of sunitinib in the adjuvant treatment of high-risk RCC

(45)

Dr. Jonasch on Alternative Sunitinib Scheduling for mRCC

(1:1econd)

Dr. McKay Discusses Combinations in Renal Cell Carcinoma

(1:21)

A Phase III Trial of Pembrolizumab as Adjuvant Treatment for Renal Cell Carcinoma

(3:1econd)